Science

Nina Niu Sanford: Phase I trial of pre-op SBRT for resectable pancreas cancer

Nina Niu Sanford/utswmed.org

Feb 13, 2025, 07:52

Nina Niu Sanford: Phase I trial of pre-op SBRT for resectable pancreas cancer

Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared an article by Mustafa M.Basree, et al. on X:

“Ph I trial of pre-op SBRT for resectable pancreas ca: R0 resection rate 100%.

Vs NORPACT1 neoadjuvant chemo arm alone R0 56%.

Await clinical outcomes, but what other disease site accepts R1 resection in ~1/2 of patients?

Pre-op RT for select resectable PDAC will be way to go.”

Neoadjuvant SBRT plus Elective Nodal Irradiation with Concurrent Capecitabine for Patients with Resectable Pancreatic Cancer: Survival Analysis of a Prospective Phase 1 Trial.

Authors: Mustafa M. Basree, et al.

Nina Niu Sanford: Phase I trial of pre-op SBRT for resectable pancreas cancer

Brigham and Women's Hospital cancer capecitabine fight against cancer Global fight against cancer Massachusetts General Hospital Nina Niu Sanford NORPACT1 OncoDaily Oncology pancreas cancer RadOnc SBRT

ACT for Children: Tackling Inequities in Childhood Cancer Through Unique Global Collaboration

Richard Gere and Alejandra Gere to Join Second Global OncoThon on February 15 for Fight Against Childhood Cancer

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%